On Monday, over 100 healthcare professionals in Canada challenged the health minister’s decision to reject their applications to access psilocybin.
In 2020, non-profit TheraPsil helped the first patients consume psilocybin through a Section 56 exemption – which waives the compound’s prohibition on a case-by-case basis.
To discuss patient advocacy and psilocybin access in Canada, PSYCH sat down with TheraPsil’s CEO Spencer Hawkswell.
READ MORE
With her late husband Alexander Shulgin, Ann Shulgin pioneered the use of psychedelic drugs in psychotherapy
Read More
Those who microdosed psilocybin saw improved mental health and mind-body coordination over a one-month period.
Read MoreFilament Health doses its first patient in natural psilocybin trial.
Cybin completes acquisition of Entheon’s DMT study.
Optimi Health finalises supply agreement with Bloom.
Psychedelic medicines in the treatment of depression.
Clairvoyant initiates Phase II psilocybin trial for AUD.
Ketamine therapy growing in popularity.
Algernon provides update on Phase I DMT trial.
Psilocybin alters thalamic connectivity.
Psychedelic medicines and self-actualisation.
Doctors request access to psychedelic medicines in New Mexico.
Florida bill aims to decriminalise psilocybin.
The Psychedelics as Medicine Report provides market intelligence from industry experts and thought leaders.
Previous sponsors include atai Life Sciences, COMPASS Pathways and Cybin.
Contact Grace@psych.global for partnership opportunities.
CONTACT FORM